Wafa Al-Jamal
    Phone: +44 (0)28 9097 2609

    For media contact email comms.office@qub.ac.uk
    or call +44(0)2890 973091.

    View graph of relations

    Research Statement

    Dr Al-Jamal is an overseas (Jordan) and a UK-registered pharmacist. She completed her PhD in Nanotechnology and Drug Delivery from London School of Pharmacy (now known as UCL School of Pharmacy), following receiving the prestigious Overseas Research Scholarship (ORS) Award from the University of London. Her PhD research project focused on developing novel liposome-based systems for combinatory therapeutic and diagnostic purposes. In 2008, Dr Al-Jamal joined UCL School of Pharmacy as a Research Fellow focusing on live animal imaging and evaluating organ biodistribution of a variety of novel gene and drug delivery vectors. In 2012, she was appointed at The Institute of Pharmaceutical Science, King’s College London as a Senior Research Associate, focusing on evaluating the behaviour and the efficacy of personalised nanomedicines to treat cancer. Dr Al-Jamal joined the University of East Anglia, Norwich, as a Lecturer in Nanomedicine and Drug Delivery (2013-2014), before being awarded a five-year Career Development Fellowship from Prostate Cancer UK, to develop novel nanomedicines targeting metastatic prostate cancer. In August 2017, Dr Al-Jamal joined Queen’s University Belfast School of Pharmacy as a Reader in Nanomedicine and Drug Delivery.

    Dr Al-Jamal is a Visiting Professor at Guizhou Medical School, Guiyang, China. She was the GSK Emerging Scientist Award winner for 2015 for her work in the field of Cancer Nanomedicine. She also received the prestigious international Gro Brundtland Award, Taiwan, that recognizes distinguished female scientists in the field of sustainable development.

     

     

    Research Interests

    Dr Al-Jamal's multidisciplinary team works on developing novel nanomedicines for combinatory therapy and theranostic applications. Currently, her research focuses on developing smart vectors for delivering a broad range of therapeutic agents, and to fabricate multifunctional nanoparticles to target cancer and other diseases. Her long-term research career is to facilitate the translation of nanoparticle-based therapeutics from the lab to the clinic.

    Willingness to take PhD. students

    Yes

    PhD projects

    I am always open to PhD applications in the field of nanopharmaceutical, targeted delivery, smart and novel nanomaterials, exosomes, immunotherapy, tumour microenvironment, and nanotoxicology.

    Frequent Journals

    • Journal of Controlled Release

      ISSNs: 0168-3659

      Elsevier

      Scopus rating (2017): CiteScore 7.9 SJR 2.684 SNIP 1.802

      Journal

    • ACS Nano

      ISSNs: 1936-0851

      American Chemical Society

      Scopus rating (2017): CiteScore 14.29 SJR 7.203 SNIP 2.58

      Journal

    • International Journal of Pharmaceutics

      ISSNs: 0378-5173

      Elsevier

      Scopus rating (2017): CiteScore 4.06 SJR 1.172 SNIP 1.27

      Journal

    • Biomaterials

      ISSNs: 0142-9612

      Elsevier BV

      Scopus rating (2017): CiteScore 9.21 SJR 3.111 SNIP 1.897

      Journal

    • Chemical Communications

      ISSNs: 1359-7345

      Additional searchable ISSN (Electronic): 1364-548X

      Royal Society of Chemistry

      Scopus rating (2017): CiteScore 6.03 SJR 2.555 SNIP 1.127

      Journal

    View all »

    View all

    View all

    ID: 133053431